Company Profile
Moderna
— A company using a single mRNA-and-LNP platform to expand from vaccines into cancer and rare diseases
Modelna is a representative company of mRNA medicine. However, sales for the20 year ended December 20,25 million yenalmost all COVID vac sHome Revenue is a deficit for 3 years. On the other hand in Europe in 2026Mixed Vaccines for Vaccines and COVIDUSAmRNA Influenza vaccines mwith approval Merck & Co.Individualized neo-antigen therapyAnnounced that the 3rd phase test achieved major evaluation items. In this article, this company isWhat to do in mRNA and lipid nanoparticles (LNP), and what to doHome We will organize only legal disclosure to the US SEC and official announcement of the company.
- Modelna in 30 seconds and standing position in drug discovery and DDS
- About logo and company name
- Where is this company in the world of drug discovery and DDS?
- COVID Vac s
- Drug discovery and DDS resources
- Past Initiatives
- Future plans
- What is DDS?
- Collaboration mapping of drug discovery and DDS
- Technologies, Products and Services
- The risk of this company
- Glossary/Source/Ins ment and Source Response Table
1. Standing position in drug discovery and DDS
Cambridge325 Binney Street（Moderna Science Center）
(Modality)Production and sales of approved products
Businesses related to drug discovery and DDS are largePharmaceutical Company / Biotech / Contract Development Manufacturing (CDMO・CRO)3 types. ModelsDrug discovery biotechOne modalitymRNA) and its carrierLNP) is a company-wide bet FactsHome 10-K is our platform3 elements of mRNA, ceramic, and manufacturing processation and definition, Vac s, cancer treatments, and rare disease treatments are explained to be made by changing the sequence, lipids and processes on the same base. The difference between general biotech is COVID vacExperienced in-house for approval, mass production and salesComment In other words, Modelna is a research company with technology, and it is also a vac manufacturer with a decrease in sales. Turning funds earned by vac s into cancer and rare diseasesThis is the key to reading this company.
2. Logo and company name
Moderna trademark In this article, we do not reproduce the generated image.
Images posted on the header of the official websiteHome img/moderna_logo.svg Contact Us
Note: The company name on legal disclosure is Moderna, Inc. Renamed from Moderna The eutics, Inc. in August 2018. Clinical trials and parties of patent litigation ModernaTX, Inc. The name comes out. In Japanese, it is written as "Modelna". The logo is "moderna".
Official Site:https://www.modernatx.com/3. Where is this company in the world of drug discovery and DDS?
TypeDrug Biotechin the center modalitiesmRNA・LNPHome FactsHome However, there are five products and factories in Japan and overseas. 10-KIn ious disease vac , cancer treatment, rare disease treatment3 franchises Cancer antigen therapy (intismeran autogene), cancer antigen therapy, T-cell enhancer, cell therapy enhancer, etc. Multiple ways to make protein in the body with mRNAThe basics of mRNA and LNP are handled by "mRNA" and "lipid nanoparticles".
4. Company size (most of sales are COVID vac s)
All numbers are subject to 10-K and 10-Q submitted to the US SEC. Unit: million USD) Facts。
| Indicators (million dollars) | FY2023 | FY2024 | FY2025 | January to June 2026 |
|---|---|---|---|---|
| Total sales | 6,848 | 3,236 | 1,944 | 534 |
| COVID(COikevax・mNEXSPIKE) | 6,671 | 3,084 | 1,810 | 436 |
| Sales: RSV(m VIA) | ― | 25 | 8 | 10 |
| R&D expenses | 4,845 | 4,543 | 3,132 | 1,300 |
| Net Loss | 4,714 | 3,561 | 2,822 | 2,125 |
| December 31, 2025 | June 30, 2026 | |
|---|---|---|
| Cash and cash equivalents + investment | 8,135 million dollars | 6,910 million dollars |
| Approx. 4,700 (18 countries, full-time employees) | 10-Q Not specified | |
| Number of Development Programs | 35 | 36 (Clinical phase candidates 26) |
$8,135 million in cash at the end of December 2025$6 billionIncluded FactsHome In July 2026, the settlement of LNP patent litigationUS$95,000Payment SeptemberUS$30 billion(0% interest rate) The sales cost of January to June 2026 is increased from $229 million to $14 million in the previous year. 2026 Cash and InvestmentUS$47 billionContact Us Prospects before Issuance of Convertible Bonds) Undetermined / FutureHome If you see only the number of sales, it is a reduction section.Waiting for the next product to rise while securing development funds with borrowings and corporate bonds2026
5. Drug discovery and DDS resources
Modelna is a company that only performs mRNA medicine.All of the company’s R&D and capital investments are invested in mRNA and LNPWe will organize the following four points: people, gold, external and public cooperation.
| Resource Types | ||
|---|---|---|
| Person | Full Time4,700 people・18 countries (December 31, 2025) 46% of doctors, doctors and mastersNon-dissemination of personnel breakdown by modalities | Facts |
| People (Research Center) | CambridgeModerna Science Center(approx. 462,000 square feet) Head office, platform research, drug discovery, clinical development) | Facts |
| Gold (R&D expenses) | FY2025 US$32 billion(31% year-on-year). About 2026$29 billionSearch | Facts |
| Gold (Manufacturing Equipment) | Acquisition of tangible fixed assets 2025 US$49,200 million(2024, $105 million) Capital investment in 2026 is expected to be $2 billion to $3 billion. For domestic re of the preparation process to Norwood (MTC)Over $40 million | Facts |
| Manufacturing base | NowoodModerna Technology CenterCommercial production and clinical supply of original medicine. acquired in December 2024, Marlborough (for intismeran, started clinical supply in September 2025),UK, Canada, AustraliaIn-house construction plant (approved in 2025). Filling and packing is also used in domestic and overseas CMOs | Facts |
| External co-development and out-licensing | Merck (intismeran; costs and profits shared equally), Vertex (inhaled mRNA for cystic fibrosis), Immatics (mRNA-4203), and Recordati (global development and commercialization rights for mRNA-3927) | Facts |
| External investment and acquisition | “We may partner with other modalities and invest in them,” said 10-K. No specific investment and acquisition project name for 2025-2026 | Not confirmed |
| License | "There is a contract to receive a license from another person". Non-dis sure of individual implementation LNP Patent Litigation with Arbutus/Genevant in March 2026 | Facts |
| Public funds and foundations | BARDA (COVID vac。, up to $1.8 billion) Contract concluded in June 2025), CEPI (H5 Pandemic Influence, up to $54 million in 3rd phase, up to $50 million in Vungdibugillo Tesla, Gates Foundation (closed in 2025) | Facts |
| Graduate School | NIH Vac) Research Center (Nipavirus, Phase 1), IAVI, S)pps Research Institute, NIH (HIV), ILCM (Critico-Na) Syndrome) | Facts |
ModelHow much does LNP use?、How much is distributed to each franchise of cancer, rare disease, and infection?not disclosed Undetermined / FutureHome 10-K is the reason for decreasing research and development costs. On the other handIncreased investment in Norovirus vac s and cancer areasI wrote. I understand the direction of the distribution, but I can say that the amount is not known as the primary information.
6. Past Initiatives
| Time | Home | |
|---|---|---|
| 2009 - 2010 | Flagship Pioneering established Newco LS18, Inc. Established in 2010 | pharmaceutical as a dedicated mRNA drug |
| FY2016 | Merck and Individualized Cancer Vaccine($2 billion in advance)Partnership between Vertex and cBio(July) Gates Foundation and Inovio Disease Framework Agreement (January) | Launched cancer and rare diseases in partnership |
| August 2018 | Company name changed from Moderna The eutics, Inc. to Moderna, Inc. | ― |
| April 2020 | BARDA to develop mRNA-1273 (COVID vac)). Up to $1.8 billion | Development that leads to first approved products |
| September to October 2022 | Merck exercises intismeran options,$250 millionpay. The world's first halves of cost and profit | Collaborative Development |
| 2023 year | Established a manufacturing facility for Marlborough (second quarter) | To a factory dedicated to personalized medicine |
| March 2024 | Blackstone Life SciencesUS$75,000Contracts based on | Development funds that pay royalty etc. at approval |
| May 2024 | RSV vac RSmRESVIA(more than 60 years old) EU August 2024, Canada November | First approved products other than COVID |
| December 2024 | Buy Norwood MTC Campus | In-house production base |
| May to June 2025 | COVID Vac COmNEXSPIKEFDA approved (high-risk persons over 65 and 12 to 64 years old). mVIA adapts to high-risk persons aged 18 to 59 | mNEXSPIKE mRNA quantity is one fifth of Spikevax |
| 2025 years | The UK, Canada and Australia factory completed approval. Marlborough began clinical supply of intinsimeran in September 2025. October, the third phase of congenital CMV prevention was discovered by the major evaluation items | Production network of local production and failure |
| November 2025 | Ares$1.5 billionHome Announced the domestic re of the preparation process for Nowood (over $140 million, target for the first half of 2027) | Integrated production from original medicine to preparation in the United States |
| January 2026 | RecordatiContact Us Developed and marketed in the world of mRNA-3927 (prepaid $50 million) | Sales of rare diseases can be left to other companies |
| March 2026 | LNP Patent Litigation with Arbutus/GenevantHome $95 million Paid in July 2026) Added up to $113 billion with condition | No future royalty about LNP of in ious disease vac s |
| April 2026 | Influence + COVID Mixed VaccinemCOMBRIAXEuropean Commission sales approval (over 50 years old) | Fourth approved product. Unavailable at the end of June 2026 |
| August 5, 2026 | Influ VacmFLUSIVA(mRNA-1010) approved by FDA. 50-64 years old is usually approved, 65 years old or olderQuick approval | 5th approved product. 65 years old or older must be checked after commercialization |
| August 19, 2026 | Merck with intismeran and KEYTRUDA3rd phase INTERpath-001 achieved key evaluation itemsand announcements | The first phase-positive result of mRNA cancer treatment (representation of both companies) |
| September 1, 2026 | Completed the issuance of $30 billion convertible bonds (2032) | Ensuring development and launch preparation funds |
Major clinical trials (cancer areas)
| Test | Phase | Main evaluation items | Results published (in comparison contrast and evaluation) |
|---|---|---|---|
| KEYNOTE-942／mRNA-4157-P201 | Phase 2b High risk after resection (stage III/IV) malignant melanoma | Recurrence Period (RFS) | intismeran+KEYTRUDACompared to KEYTRUDA aloneLow risk of recurrence or death (HR 0.510, 95% CI 0.294–0.887).approx. 5 yearsHome Non-Blind Test |
| INTerpath-001（NCT05933577） | Phase 3 Stage IIB-IV skin malignant melanoma after resection, 1,137 people randomized in 2:1 | RFS (main), non-remote survival (DMFS, critical sub-second) | Comparison with KEYTRUDA alone groupPredefinedanalysisRFS and DMFS were statistically significantly improved (August 19, 2026).Unpublished numbersHome Tests continue to evaluate all survival periods |
The above results are written as the company's announcement.This article does not recommend the choice of treatmentHome intismeran as of September 2026Products under development (phase 3) not approved in any countryHome These are the stages of discussions with regulatory authorities and applications. Undetermined / Future。
7. Future plans
| Products | modalities and administration | Stage (as of September 2026) | The following section shows the company |
|---|---|---|---|
| intismeran（mRNA-4157／V940） | Individualized mRNA+LNP, intramus injection | 3rd phase Phase 2 and Phase 3 Test | Meetings with Merck and regulatory authorities Undetermined / Future |
| mRNA-3927 | 2 types of mRNAs are enclosed in LNP, intravenous administration | Under development (test for approval application). Total number of target cases) | The possibility of data in 2026. Sales Recordati Undetermined / Future |
| mRNA-3705 | mRNA+LNP, intravenous administration | Developed (2nd phase) | Postponement of Pibutar test judgment to mRNA-3927 data Undetermined / Future |
| VX-522 | mRNAInhalation (nebulizer)to lung | Developed (upgraded doses of phase 1/2 and iteration) | Data in late 2026 (with Vertex) Undetermined / Future |
| mRNA-1083 | mRNA+LNP, intramus、 injection | EU approval. Japan, Canada, Australia | The United States waits for FDA guidelines for re-application Undetermined / Future |
| mRNA-1403 (Norovirus) | 3 value mRNA+LNP | 3rd phase Additional cohorts are not delivered to the standard of early success by intermediate analysis | Test Co ity Undetermined / Future |
| mRNA-4359 | mRNA antigenizing IDO/PD-L1 | Developed (2nd phase) | Cohort of melanoma and non-small cell lung cancer in the second phase Undetermined / Future |
10-K in、ious disease vac、s in the coming few yearsUp to 6 approved productsClose CashInvesting in the treatment of cancer and rare diseasesI have stated the policy FactsHome In addition, I wrote that there are multiple growth opportunities in 2027 and 2028.
10-K・10-Q Undetermined / Future。
intismeranApplication period and application country/INTerpath-001Numbers such as hazard ratio/intismeranPharmaceutical price and production cost for one person/ mRNA-3927Approval timingFactoryProduction capacity (number of dozens and lots)/LNPFat composition and source/ Cancer and Rare Disease FranchiseR&D expensesHome The number "modelna cancer vac。 is released in the year of the year" and "$ billion in sales" is often caused by a report or a survey company estimate, and this article does not adopt it.
8. What is this company aiming for drug discovery and DDS?
This includes parts that the company does not directly state.Calculation in the range that can be read from primary informationand write with the basis.
| Read | Primary Information | |
|---|---|---|
| In ious disease vacCancer and Rare Diseases | 10-K stated that "Investment of cash born from in」ious products in cancer and rare diseases" | Facts |
| Life in the cancer areaIndividualized neo-antigen therapyThe source of the competitivenessManufacturingHome | Intismeran is a "scale-out type" that creates a single lot for each patient, and 10-K explains more about it if you build a dedicated Marl factory and connect from design to manufacturing with AI. | |
| Rare DiseaseIn-house development and salesSelect a share | MRNA-3927 leads the world’s sales right to Recordati, and contracts that Modelna leads clinical development until approval | |
| LNPI want to spread the destination to other than liver and muscle | VX-522 is positioned as "a demonstration of our first inhalation mRNA treatment" and is with inhalation, intratumor administration and systemic administration to the claim range of 10-K LNP patents | |
| VacLocal production with governmentsStable demand | In 10-K, the government promises to purchase multiple years by establishing its own factory in the UK, Canada and Australia | |
| For repetitive administration of the eutic drugLNP Immune PrimaryFocus on | 10-K, LNP, which changed the surface characteristics, says, “Iterative doses did not have a very low blood pressure, hepatic disorder, and immune activation.” | Facts |
8-K resolves all global litigations on Spikevax and mVIA for the settlement with Arbutus/Genevant in March 2026, including mNEXSPIKE, mCOMBRIAX and future vaccinesTotal In ious Disease PortfolioI have written that it brings certainty without future royalty. FactsHome here is theInfectionThere are no references to rare disease treatment drugs that use LNP intravenous administration and intismeran intramus administration. The effect of Japanese settlement isIsolation of intellectual property risk of vac businessIn the center, LNP on the pharmaceutical side can be read as there is a possibility that there is a separate review left Undetermined / FutureHome However, the accuracy of the contract has not been disclosed, this is the interpretation of this article. In addition to the fixed amount of $95,000 million, the Japanese settlement is the result of the appeal to the U.S. government to deal with the amount sold.Up to $13 billionAdd.
9. Collaboration mapping of drug discovery and DDS
10. Technologies, Products and Services
Approved products (as of September 2026)
| Product Name (Development Code) | Main approval (country, type, time) | 2025 Product Sales | |
|---|---|---|---|
| Spikevax（mRNA-1273） | COVID-19 | Approved in the U.S. 2025-2026 Composition approved by the FDA and approved by 40 countries | COVID Total $18 billion |
| mNEXSPIKE（mRNA-1283） | COVID-19 | U.S. FDA May 2025 (High-risk persons over 65 years old, 12 to 64 years old). Approved in Europe, Canada and Australia | Included in the above line |
| mRESVIA（mRNA-1345） | RSV | U.S. FDA May 2024 (over 60 years old) Expanded to high-risk persons aged 18-59 in June 2025. EU August 2024, Canada November 2024 | US$88.00 |
| mCOMBRIAX（mRNA-1083） | +COVID-19 | Commission April 2026 (over 50) | Un d (As of June 2026) |
| mFLUSIVA（mRNA-1010） | Seasonal | USA FDA August 5, 2026. 50-64 years old is usually approved, and 65 years old or older is approved quickly (required) | Approval 2026 |
The third phase test (NCT06602024), which was based on the approval of the 50-64-year-old of mFLUSIVA, has registered 40,805 persons over the age of 11 countries. Compare the standard doses of existing implant vaccinesThe relative efficacy of RT-like disease determined by RT-PCR is the main evaluation item. Fast approval over 65 years oldCompare the high-dose vaccinesBased on NCT05827978, 2,992 FactsHome Please do not evaluate the inferiority of vac。s.
Technology base: mRNA, LNP, manufacturing process
| s | 10-K Description |
|---|---|
| Chemical of mRNA | TLR3/7/8, RIG-IChemical Qualified UridineUse |
| Array design | 5’s unique array of non-translation areas and optimization of code areas to increase the amount of protein per。. 3' Non-Translation AreaMicroRNA binding siteTurn on the target cells to suppress translation |
| LNP Composition | Amino lipids, lipid, cholesterol, PEG lipids4 ingredients. Unique amino lipids are designed to avoid immune system and be biodegraded faster |
| LNP Surface | Reduces the characteristics of the surface that is identified by iteration and enables iteration of the the eutic drug |
| Production Process | Cell-freein vitroRNA impurities with proprietary purification by synthesizing mRNA. LNP dissolved 4 components into ethanol and mixed with mRNA in water-based buffer fluid |
| Production supply | Maximum per month1,000 lotsCreates mRNA sequences and preparations for several weeks from array to final product. Size: 1~1,000mg |
| Manufacture of personalized medicine | Automatically design intismeran from the array data of the tumor,Single-useOne lot per patient in production (scale out). Code up to 34 neo-antigens to 1 mRNA |
| Property | Over 260 U.S. patents (including applications and permissions) and over 140 U.S. patents. The final expiration of approved products is 2041, 2036, Europe (before extension) |
10-K, as an element that affects LNP performanceStructure of fat one by one、4 Composition ratio、Particle contentHome andAssembly and purification process conditions FactsHome From the material side, there are three points. (1) (1) Design of aminolipids: It is necessary to keep the ability to get out of the endsome while putting the binding (biodegradable) that is quickly dissolved in the body. (2) (2) PEG lipids and surfaces: While particleizing particles, it is also a part that is easily recognized as antibodies in iteration, and 10-K is written that it has been modified here. (3) Mixing and purification of ethanol phase and water phase: In the process of removing particles that were not enclosed, and the size was removed, 10-K expresses that this process condition depends on the orientation.
Another thing that can not be missed is the settlement in March 2026US$95,000LNP How to make lipidsDirectly connect to the cost of intellectual property as well as the effectiveness of the productThis amount indicates. In addition, 10-K writes that the production of DNA plus hyaluronic acid and low-quality (e.g. lipids) was imported into the company Raw materialsIt is said that the supply is stable and the means of quality control. Specific chemical structures and suppliers of lipids are not disclosed Undetermined / Future。
11. Risks that this company has
| Risks | ||
|---|---|---|
| Sales to the Inc. for COVID vaccines | COVID of $18 billion in product sales of $18 billion in 2025 Reduced demand for sales from 2023 to 1/3 | Facts |
| Red letter | Net loss is $47 billion, $36 billion and $28 billion in 2023 to 2025. US$21,25 million losses in the first half of 2026 | Facts |
| Addition of patent settlement | Arbutus/GenevantUp to $13 billionPay by Add | Facts |
| Terms of borrowing | Ares loans have a minimum of $5 billion per weekend ($7.5 billion in borrowings) Unapproved for over $50 billion market capital. US$30 billion | Facts |
| Development failure | The third phase of congenital CMV prevention has not been evaluated (October 2025). The third phase of Norovirus does not meet the criteria for early success by intermediate analysis. Five programs were disclosed in 2025 | Facts |
| Uncertainty of regulatory decisions | In February 2026, mRNA-1010 received a reference-to-File notification from the FDA. Over 65 years of age is fast-approved, resulting in confirmation test | Facts |
| Personalized Medicine | 1 lot per patient. The drug price, production cost, and supply capacity are not publicly announced, and it is not possible to verify whether it is profitable on a commercial scale. | |
| Re ratory vac market seasonality | 10-K explains the U.S. market “customers dispersed, orders are not predictable, shipping is seasonal.” Depends on the recommendation of public health authorities | Facts |
12. Glossary
- mRNA
- A diagram of design drawings that capture DNA information and make protein into cells. It is relatively fast decomposition in the body
- LNP
- A grain of fatty from dozens to hundreds of nm in diameter to carry into the cells. It is common to make with four types of fat.
- Aminolipid (ionized fat)
- LNP's core lipids. It plays a role to charge and release mRNA to cell quality in acidic endomes.
- Antigen
- Antigens that are not in normal cells, resulting from gene mutations of cancer cells. different for each patient.
- Personalized Antigen Therapy (INT)
- How to analyze patient tumors and make mRNA to code those human-specific neo-antigens.
- Quick approval
- US system. Approves clinical benefits based on alternative indicators that can be reasonably predicted and seek confirmation tests after the market.
- Hazard ratio (HR)
- The ratio of the speed of one event (such as recurrence or death) between the two groups. The smaller the number, the more difficult the comparison.
- Form 10-K
- Annual report of U.S. listed companies submit to US SEC. Audited and legal liability.
Concept diagram of AI generation13. Source
- Moderna, Inc. Form 10-K for the year ended December 31, 2025 Business description, platform (mRNA, LNP, manufacturing process), platform, approved products, manufacturing base, partnership (Merck, Vertex, Immatics, Recordati, BARDA, CEPI, ILCM, Gates Foundation, Blackstone), patent, number of employees, sales, R&D costs, net loss, cash, and risk https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm
- Moderna, Inc. Form 10-Q for the quarterly period ended June 30, 2026 mCOMBRIAX European approval, VRBPAC vote, CEPI expansion, sales, R&D expenses, net loss, cash, Recordati contract conditions, Norovirus phase 3 interim analysis, development number https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm
- Moderna, Inc. Consolidated Financial Results for the Second Quarter of the Fiscal Year Ended March 31, 2019 (Submitted July 31, 2019) Financial forecasts for 2026 (sales, R&D expenses, capital investment, year-end cash), and settlement of Japanese money of $95,000. https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/exhibit9912026q2pressrelea.htm
- Moderna, Inc. Form 8-K (US SEC submission, March 5, 2026) March 3, 2026 The reconcil。 of patent litigation with Arbutus Biopharma/Genevant Sciences, a payment of $95,000 million and a conditional payment of up to $13 billion, an effect on the in。ious portfolio. https://www.sec.gov/Archives/edgar/data/1682852/000168285226000047/mrna-20260303.htm
- Moderna, Inc. Form 8-K (US SEC submission, November 24, 2025) (November 19, 2025) Minimum cash conditions with a loan frame of $1.5 billion as a representative of Ares Capital. https://www.sec.gov/Archives/edgar/data/1682852/000162828025053816/mrna-20251119.htm
- Moderna, Inc. Form 8-K 0% convertible bond (expired in 2032) https://www.sec.gov/Archives/edgar/data/1682852/000119312526378505/d108896d8k.htm
- Moderna, Inc. FDA Approval for Influ Vac mFLUSIVA Company IR website news distribution page). The scope of approval (50 to 64 years old usually approved, fast approval over 65 years old), the design and scale of the base test. https://feeds.issuerdirect.com/news-release.html?newsid=4801915282452025&symbol=MRNA
- Merck & Co.／Moderna, Inc. "Merck and Moderna Announce Phase 3 INTerpath-001" 5 years data of INTerpath-001's primary evaluation item achieved, test design (1,137 people, 2:1), KEYN。-942. https://news.modernatx.com/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-plus-keytruda-met-endpoints-of-rfs-and-dmfs-in-melanoma
- Moderna, Inc. Press Release: Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities. The company has invested over $140 million in the domestic reconfiguration of the preparation process for Nowood, with a goal of completion by 2027. https://feeds.issuerdirect.com/news-release.html?newsid=5477880263899463&symbol=MRNA
- ClinicalTrials.gov NCT05933577 (INTerpath-001/V。-001, Phase 3, RFS) https://clinicaltrials.gov/study/NCT05933577
- ClinicalTrials.gov NCT06602024 (3rd phase of mRNA-1010, over 50 years old, contrast to existing vac。s). https://clinicaltrials.gov/study/NCT06602024
- Moderna, Inc. Official website (name and logo) https://www.modernatx.com/
14. Response table of claims and sources
| Content | ||
|---|---|---|
| Renamed as official name, head office location, listed market, and predecessor company (August 2018) | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm |
| Company description, development program 36, candidate for clinical stage 26 | Facts | Source 2 https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm |
| Total sales, product sales, R&D expenses, net loss, acquisition of tangible fixed assets from 2023 to 2025 | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm |
| $534 million in sales for the first half of 2026, R&D and net loss, $6,910 million in cash and investments as of June 2026 | Facts | Source 2 https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm |
| 4,700 employees, 18 countries, 46% degree holders, and the scale and application ofererna Science Center | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm |
| 3 elements of the platform (mRNA, hyaluronic acid, manufacturing process), modifier uridine, microRNA binding site, LNP four components, biodegradable aminolipid, and iteration | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm |
| Up to 1,000 research-use lots per month; automated design of intismeran and scale-out production using single-use systems; in-house production of DNA plasmids and small molecules | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm |
| MTC, Marlborough, UK, Canada and Australia | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm |
| re of the preparation process (over $140 million, target for the first half of FY2015) | Facts | Source 9 https://feeds.issuerdirect.com/news-release.html?newsid=5477880263899463&symbol=MRNA |
| Partnership with Merck (2016; $200 million upfront, $250 million in 2022, with costs and profits shared equally) and relationships with Vertex, Immatics, the Gates Foundation, BARDA, CEPI, ILCM, and Blackstone | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm |
| 5,000ing to Recordati (prepaid $50 million, development and approval milestone up to $10 million), CEPI's Vendibugillo Tesla up to $50 million | Facts | Source 2 https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm |
| Spikevax, mNEXSPIKE, mRNAVIA approval status (country, time, target), mNEXSPIKE mRNA volume is 1/5 of Spikevax | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm |
| European Commission approval of mCOMBRIAX (April 2026, for adults aged 50 and older) and its not-yet-launched status as of June 2026 | Facts | Source 2 https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm |
| mFLUSIVA FDA approval (August 5, 2026, 50-64, usually approved, 65 years or older) and ground test design | Facts | Source7・11 https://feeds.issuerdirect.com/news-release.html?newsid=4801915282452025&symbol=MRNA |
| ususal-to-File notification and modification application for mRNA-1010 | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm |
| KEYN -942 5-year data (compared with HR 0.510, 95% CI 0.294–0.887, KEYTRUDA alone group) | Facts | Source 1・8 https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm |
| INTerpath-001 achieves RFS and DMFS with intermediate analysis, randomization of 1,137 people and 2:1, NCT number and key evaluation items | Facts | Source 8・10 https://news.modernatx.com/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-plus-keytruda-met-endpoints-of-rfs-and-dmfs-in-melanoma |
| Reconcil) with Arbutus/Genevant (up to $95,000, with a conditional payment of up to $13 billion, effect on in)ious portfolio) | Facts | Source 4 https://www.sec.gov/Archives/edgar/data/1682852/000168285226000047/mrna-20260303.htm |
| Payment of Japanese settlement in July 2026 and financial forecasts in 2026 (up to 10% of sales, R&D expenses: $29 billion, capital investment: $2 trillion to $3 billion, year-end cash: $47 trillion to $52 billion) | Facts | Source 3 https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/exhibit9912026q2pressrelea.htm |
| Minimum cash conditions with a $15 billion loan frame | Facts | Source 5 https://www.sec.gov/Archives/edgar/data/1682852/000162828025053816/mrna-20251119.htm |
| Issuance of $30 billion convertible bonds (fiscal year 2032) | Facts | Source 6 https://www.sec.gov/Archives/edgar/data/1682852/000119312526378505/d108896d8k.htm |
| Number of patents (over 260 U.S., over 140 U.S., 485 U.S.) and expiration date of approved products | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm |
| CMV phase 3 success, 2025 discovery program, Norovirus phase 3 interim analysis | Facts | Source 1・2 https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm |
| Drug discovery and DDS classification (pharmaceu company / drug discovery biotech / contract development manufacturing and research) | The calculation of this paper | This article. Company name is an example of a company handled by this series. |
| Intismeran application period, pharmaceutical price, production cost, INTERpath-001 number, production capacity of each factory, LNP fat composition and supply source, R&D costs by franchise | Undetermined / Future | Not specified in the source 1-8. No number of media and survey companies https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm |
| 2025-2026 Individual investment and acquisition projects, individual implementation (licensing) projects | Undetermined / Future | Not listed in Source 1 and 2. This article does not break even if it is not present https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm |
| Read that the source of competitiveness in the cancer area is manufactured | Interpre of this paper from the description of the production of source 1 | |
| A rare disease reads that the development of the company and the sales of the product to other companies. | Interpre of this document from the Recordati contract of Source 2 | |
| Read how to spread LNP destinations to other than liver and muscle | Positioning of VX-522 in Source 1 and interpretation of this paper from the scope of patent billing | |
| Read to Stabilize Demand by Local Production | Interpre of this paper from each country factory and purchase promise of source 1 | |
| Interpretation that the LNP patent settlement primarily affects the vaccine business, while the therapeutic side may require separate consideration | Inference | This article’s interpretation based on Source 4, which refers only to the infectious-disease portfolio |
| Risks related to individualized medical business | Interpre of this article from the non-publication of pharmaceutical price, cost and supply capacity |
Last Updated:September 26, 2026/Troy Technical
All figures in this article are based on the legal disclosure document submitted byererna, Inc. to the US Securities and Exchange Commission (SEC), the official announcement of the company, and ClinicalTrials.gov. We do not use estimates and media-based numbers of survey companies. The "、ulation" section is an interpretation that the article reads from the primary information and is not an announcement of the company. This article is not medical advice.